Nasdaq Vigl News Today : Breaking News, Live Updates & Top Stories | Vimarsana

– Reported positive interim data from Phase 2 IGNITE proof-of-concept clinical trial evaluating iluzanebart (VGL101) for treatment of ALSP – – Enrollment...

Vigil Neuroscience, Inc. (NASDAQ:VIGL – Get Free Report)’s share price traded down 2.5% during trading on Tuesday . The company traded as low as $3.47 and last traded at $3.54. 78,504 shares traded hands during trading, a decline of 70% from the average session volume of 264,717 shares. The stock had previously closed at $3.63. […]

Vigil Neuroscience, Inc. (NASDAQ:VIGL – Get Free Report)’s share price was down 0.3% during trading on Monday . The company traded as low as $3.52 and last traded at $3.59. Approximately 74,794 shares changed hands during mid-day trading, an increase of 27% from the average daily volume of 58,771 shares. The stock had previously closed […]

Vigil Neuroscience, Inc. (NASDAQ:VIGL – Get Free Report) CEO Ivana Magovcevic-Liebisch bought 4,000 shares of the business’s stock in a transaction on Monday, November 20th. The stock was purchased at an average cost of $3.75 per share, with a total value of $15,000.00. Following the purchase, the chief executive officer now owns 207,687 shares of […]

Wedbush reiterated their outperform rating on shares of Vigil Neuroscience (NASDAQ:VIGL – Free Report) in a report published on Friday, Benzinga reports. Wedbush currently has a $23.00 price objective on the stock. Several other equities analysts have also recently commented on VIGL. JMP Securities began coverage on shares of Vigil Neuroscience in a research report […]